Cargando…
Attenuated measles virus as a vaccine vector
Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707277/ https://www.ncbi.nlm.nih.gov/pubmed/17303293 http://dx.doi.org/10.1016/j.vaccine.2007.01.064 |
_version_ | 1782276492843024384 |
---|---|
author | Zuniga, Armando Wang, ZiLi Liniger, Matthias Hangartner, Lars Caballero, Michael Pavlovic, Jovan Wild, Peter Viret, Jean Francois Glueck, Reinhard Billeter, Martin A. Naim, Hussein Y. |
author_facet | Zuniga, Armando Wang, ZiLi Liniger, Matthias Hangartner, Lars Caballero, Michael Pavlovic, Jovan Wild, Peter Viret, Jean Francois Glueck, Reinhard Billeter, Martin A. Naim, Hussein Y. |
author_sort | Zuniga, Armando |
collection | PubMed |
description | Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion of exogenous genes encoding foreign antigens into the MV genome in such a way that they can be expressed by the MV vaccine strain, without affecting virus structure, propagation and cell targeting. Recombinant viruses rescued from cloned cDNA induce immune responses against both measles virus and the cloned antigens. The tolerability of MV to gene(s) insertion makes it an attractive flexible vector system, especially if broad immune responses are required. The fact that measles replication strictly occurs in the cytoplasm of infected cells without DNA intermediate has important biosafety implications and adds to the attractiveness of MV as a vector. In this article we report the characteristics of reporter gene expression (GFP, LacZ and CAT) and the biochemical, biophysical and immunological properties of recombinant MV expressing heterologous antigens of simian immunogeficiency virus (SIV). |
format | Online Article Text |
id | pubmed-3707277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-37072772013-07-10 Attenuated measles virus as a vaccine vector Zuniga, Armando Wang, ZiLi Liniger, Matthias Hangartner, Lars Caballero, Michael Pavlovic, Jovan Wild, Peter Viret, Jean Francois Glueck, Reinhard Billeter, Martin A. Naim, Hussein Y. Vaccine Article Live attenuated measles virus (MV) vaccines have an impressive record of safety, efficacy and ability to induce life-long immunity against measles infection. Using reverse genetics technology, such negative-strand RNA viruses can now be rescued from cloned DNA. This technology allows the insertion of exogenous genes encoding foreign antigens into the MV genome in such a way that they can be expressed by the MV vaccine strain, without affecting virus structure, propagation and cell targeting. Recombinant viruses rescued from cloned cDNA induce immune responses against both measles virus and the cloned antigens. The tolerability of MV to gene(s) insertion makes it an attractive flexible vector system, especially if broad immune responses are required. The fact that measles replication strictly occurs in the cytoplasm of infected cells without DNA intermediate has important biosafety implications and adds to the attractiveness of MV as a vector. In this article we report the characteristics of reporter gene expression (GFP, LacZ and CAT) and the biochemical, biophysical and immunological properties of recombinant MV expressing heterologous antigens of simian immunogeficiency virus (SIV). Elsevier Ltd. 2007-04-20 2007-02-02 /pmc/articles/PMC3707277/ /pubmed/17303293 http://dx.doi.org/10.1016/j.vaccine.2007.01.064 Text en Copyright © 2007 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zuniga, Armando Wang, ZiLi Liniger, Matthias Hangartner, Lars Caballero, Michael Pavlovic, Jovan Wild, Peter Viret, Jean Francois Glueck, Reinhard Billeter, Martin A. Naim, Hussein Y. Attenuated measles virus as a vaccine vector |
title | Attenuated measles virus as a vaccine vector |
title_full | Attenuated measles virus as a vaccine vector |
title_fullStr | Attenuated measles virus as a vaccine vector |
title_full_unstemmed | Attenuated measles virus as a vaccine vector |
title_short | Attenuated measles virus as a vaccine vector |
title_sort | attenuated measles virus as a vaccine vector |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707277/ https://www.ncbi.nlm.nih.gov/pubmed/17303293 http://dx.doi.org/10.1016/j.vaccine.2007.01.064 |
work_keys_str_mv | AT zunigaarmando attenuatedmeaslesvirusasavaccinevector AT wangzili attenuatedmeaslesvirusasavaccinevector AT linigermatthias attenuatedmeaslesvirusasavaccinevector AT hangartnerlars attenuatedmeaslesvirusasavaccinevector AT caballeromichael attenuatedmeaslesvirusasavaccinevector AT pavlovicjovan attenuatedmeaslesvirusasavaccinevector AT wildpeter attenuatedmeaslesvirusasavaccinevector AT viretjeanfrancois attenuatedmeaslesvirusasavaccinevector AT glueckreinhard attenuatedmeaslesvirusasavaccinevector AT billetermartina attenuatedmeaslesvirusasavaccinevector AT naimhusseiny attenuatedmeaslesvirusasavaccinevector |